Amanda Curtis
Physician Assistant · Rahway, NJNPI 1790065977
Payments from drug & device makers
Across 410 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$879
- AstraZeneca$717
- AbbVie$619
- GSK$377
- Pfizer$334
- Novo Nordisk$321
- plus $3K from 38 others
What the payments were for
- Food & beverage$6,298100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$125
- STELARA$125
- Tremfya$125
- FREESTYLE LIBRE 3$115
- JARDIANCE$113
How this compares
$6,299 in reported general payments places this provider in the 95th percentile of 2,726 physician assistant providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $128,757 |
| MounjaroTirzepatide | 95 | $102,102 |
| FarxigaDapagliflozin Propanediol | 87 | $94,982 |
| JardianceEmpagliflozin | 55 | $65,576 |
| EliquisApixaban | 32 | $35,938 |
| JanuviaSitagliptin Phosphate | 22 | $31,950 |
| RybelsusSemaglutide | 25 | $30,389 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $23,602 |
| TradjentaLinagliptin | 21 | $22,915 |
| CaplytaLumateperone Tosylate | 11 | $18,270 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $17,753 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $16,143 |
| LinzessLinaclotide | 19 | $15,943 |
| XareltoRivaroxaban | 12 | $15,313 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $14,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $321 | $159,146121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $717 | $109,755107 claims |
| Lilly USA, LLCMounjaro | $879 | $102,10295 claims |
| Boehringer IngelheimJardiance, Tradjenta | $309 | $88,49176 claims |
| PfizerEliquis | $334 | $35,93832 claims |
| MerckJanuvia, Janumet Xr | $130 | $35,86135 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $377 | $26,59232 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $104 | $18,27011 claims |
| AbbVieLinzess | $619 | $15,94319 claims |
| Johnson & JohnsonXarelto | $109 | $15,31312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,726 physician assistant providers in New Jersey.
Other physician assistant in Rahway
- Alexa HetzelEast Windsor$750K
- Nicole Schmid DavisHamilton$148K
- Todd NewmanHoboken$73K
- Patrick McGinnShrewsbury$72K
- Tatiana Dell'aquilaNutley$43K
- Nicole ColucciRiverdale$36K
- Salvatore SciurbaMiddletown$25K
- Jacqueline CristiniEdison$22K
- Mark MazakLakewood$21K
- Andrea BarkerPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.